Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts
Yamatodani, Takashi LU ; Holmqvist, Bo LU ; Kjellén, Elisabeth LU ; Johnsson, Anders LU ; Mineta, Hiroyuki and Wennerberg, Johan LU
(2012)
In Acta Oto-Laryngologica
132(12).
p.1324-1333
- Abstract
- Conclusion: The study showed the value of using intravital microscopy (IVM) analysis for the study of neoangiogenesis. It demonstrated that the model and the analytical methodology could be used to evaluate in detail the effects of treatment strategies for solid tumours. Objectives: Neoangiogenesis is a key component of tumour progression, invasion and metastasis. In clinical trials monoclonal antibodies specific for vascular endothelial growth factor - VEGF (bevacizumab) - have been shown to significantly affect tumour progression when given in combination with standard chemotherapy, and also to improve the overall survival of patients. For squamous cell carcinoma of the head and neck (HNSCC), we still await definitive evidence of the... (More)
- Conclusion: The study showed the value of using intravital microscopy (IVM) analysis for the study of neoangiogenesis. It demonstrated that the model and the analytical methodology could be used to evaluate in detail the effects of treatment strategies for solid tumours. Objectives: Neoangiogenesis is a key component of tumour progression, invasion and metastasis. In clinical trials monoclonal antibodies specific for vascular endothelial growth factor - VEGF (bevacizumab) - have been shown to significantly affect tumour progression when given in combination with standard chemotherapy, and also to improve the overall survival of patients. For squamous cell carcinoma of the head and neck (HNSCC), we still await definitive evidence of the effect of such treatment. The present study was designed to investigate the anti-angiogenesis effect of beviacizumab in green fluorescent protein (GFP)-labelled HNSCC xenografts using IVM technology. Methods: We performed IVM and used image analysis for quantification of angiogenesis and of effects of bevacizumab on cell viability, combined with histochemical and immunohistochemical analysis to standardize the digital analysis of changes in tumour vascularization and cell viability. Results: We found significant effects of bevacizumab on angiogenesis and cancer cell survival in HNSCC. Repeated injections of bevacizumab were found to provide the greatest effects. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3379352
- author
- Yamatodani, Takashi
LU
; Holmqvist, Bo
LU
; Kjellén, Elisabeth
LU
; Johnsson, Anders
LU
; Mineta, Hiroyuki
and Wennerberg, Johan
LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Head and neck cancer, bevacizumab, neoangiogenesis, vascularization
- in
- Acta Oto-Laryngologica
- volume
- 132
- issue
- 12
- pages
- 1324 - 1333
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000311550800014
- scopus:84869749239
- pmid:23039202
- ISSN
- 1651-2251
- DOI
- 10.3109/00016489.2012.699195
- language
- English
- LU publication?
- yes
- id
- 1591ba23-6436-4b88-8482-4551b3e15ea5 (old id 3379352)
- date added to LUP
- 2016-04-01 13:29:31
- date last changed
- 2022-01-27 19:30:53
@article{1591ba23-6436-4b88-8482-4551b3e15ea5,
abstract = {{Conclusion: The study showed the value of using intravital microscopy (IVM) analysis for the study of neoangiogenesis. It demonstrated that the model and the analytical methodology could be used to evaluate in detail the effects of treatment strategies for solid tumours. Objectives: Neoangiogenesis is a key component of tumour progression, invasion and metastasis. In clinical trials monoclonal antibodies specific for vascular endothelial growth factor - VEGF (bevacizumab) - have been shown to significantly affect tumour progression when given in combination with standard chemotherapy, and also to improve the overall survival of patients. For squamous cell carcinoma of the head and neck (HNSCC), we still await definitive evidence of the effect of such treatment. The present study was designed to investigate the anti-angiogenesis effect of beviacizumab in green fluorescent protein (GFP)-labelled HNSCC xenografts using IVM technology. Methods: We performed IVM and used image analysis for quantification of angiogenesis and of effects of bevacizumab on cell viability, combined with histochemical and immunohistochemical analysis to standardize the digital analysis of changes in tumour vascularization and cell viability. Results: We found significant effects of bevacizumab on angiogenesis and cancer cell survival in HNSCC. Repeated injections of bevacizumab were found to provide the greatest effects.}},
author = {{Yamatodani, Takashi and Holmqvist, Bo and Kjellén, Elisabeth and Johnsson, Anders and Mineta, Hiroyuki and Wennerberg, Johan}},
issn = {{1651-2251}},
keywords = {{Head and neck cancer; bevacizumab; neoangiogenesis; vascularization}},
language = {{eng}},
number = {{12}},
pages = {{1324--1333}},
publisher = {{Taylor & Francis}},
series = {{Acta Oto-Laryngologica}},
title = {{Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts}},
url = {{http://dx.doi.org/10.3109/00016489.2012.699195}},
doi = {{10.3109/00016489.2012.699195}},
volume = {{132}},
year = {{2012}},
}